KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Deferred Revenue: 2011-2017

Historic Current Deferred Revenue for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Dec 2017 value amounting to $287,000.

  • Supernus Pharmaceuticals' Current Deferred Revenue rose 37.32% to $287,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $287,000, marking a year-over-year increase of 37.32%. This contributed to the annual value of $287,000 for FY2017, which is 37.32% up from last year.
  • According to the latest figures from Q4 2017, Supernus Pharmaceuticals' Current Deferred Revenue is $287,000, which was down 0.00% from $287,000 recorded in Q3 2017.
  • In the past 5 years, Supernus Pharmaceuticals' Current Deferred Revenue ranged from a high of $417,000 in Q1 2013 and a low of $143,000 during Q2 2014.
  • Moreover, its 3-year median value for Current Deferred Revenue was $208,000 (2016), whereas its average is $215,417.
  • Data for Supernus Pharmaceuticals' Current Deferred Revenue shows a peak YoY increase of 79.74% (in 2013) and a maximum YoY decrease of 59.84% (in 2013) over the last 5 years.
  • Supernus Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $204,000 in 2013, then fell by 29.90% to $143,000 in 2014, then rose by 23.08% to $176,000 in 2015, then grew by 18.75% to $209,000 in 2016, then spiked by 37.32% to $287,000 in 2017.
  • Its Current Deferred Revenue was $287,000 in Q4 2017, compared to $287,000 in Q3 2017 and $287,000 in Q2 2017.